Vice President, Drug Safety & Pharmacovigilance

Benefits

Parental leave

Not verified

Non-birth-parent leave

Not verified

Family-building benefits

• Fertility benefits: Not verified
• Adoption assistance: Not verified
• Surrogacy assistance: Not verified

Mental health support

Not verified

Relocation assistance

Not verified

Childcare support

Not verified

Learning budget

Not verified

Verification

Not verified

Salary

$330K-$400K From the posting source checked Jun 20, 2026

401(k) match

Not verified

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)

$81,444 U.S. median for this role

Projected growth (BLS Employment Projections)

+6.9% - Faster than average

348% above the BLS role benchmark for healthcare aggregate.

Posted salary is far from this role benchmark; treat it as low confidence.

Matched to SOC 29-1141 - Healthcare aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Role

Role function

Healthcare From the posting source checked Jun 20, 2026

Seniority

Director Plus From the posting source checked Jun 20, 2026

Work mode

Hybrid From the posting source checked Jun 20, 2026

In-office days

2 days From the posting source checked Jun 20, 2026

Schedule

Shift type

Not verified

Weekend work

Not verified

Company

Company stage

Growth-stage From the posting source checked Jun 20, 2026

Application

Cover letter

Not verified

Assessment

Not verified

Deadline

Not stated

Where they hire

State eligibility is not yet verified.

About this role

Vice President, Drug Safety & Pharmacovigilance San Francisco, CA or Remote or Hybrid About us: Braveheart Bio is a Bay Area-based biopharmaceutical company pioneering best-in-class therapies for cardiovascular disease. Our lead program is a next-generation myosin inhibitor, licensed from Hengrui Pharma, being developed to transform the treatment of hypertrophic cardiomyopathy (HCM)-the most common inherited cardiac disease. Currently in Phase 3 clinical development in China for the more common obstructive form of HCM, our candidate has demonstrated a compelling clinical profile that may position it as a best-in-class therapy with meaningful differentiation. With a proven leadership team, a strong financial foundation, and a high-value late-stage asset, Braveheart Bio represents an outstanding opportunity for ambitious, mission-driven professionals to make a tangible impact in a high-profile and rapidly evolving therapeutic area. The role: The Vice President, Drug Safety and Pharmacovigilance will lead and scale the global drug safety and pharmacovigilance function at Braveheart Bio. Reporting into the Chief Medical Officer, the VP is accountable for the safety strategy and integrated benefit-risk profile across the portfolio, with immediate focus on supporting Phase 3 programs and preparing the organization for NDA submission and post-marketing readiness. The VP will partner with an established Senior Director of PV (a direct report) to design the PV operating model, select CRO/PV vendor partners, establish the safety governance framework, and represent Safety in cross-functional and regulatory interactions. This individual will be hands-on while setting strategic direction and has a track record of leveraging external partners to deliver inspection-ready DSPV at

Read the full description at job-boards.greenhouse.io. FewerJobs shows a preview and links to the original posting.